A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Inclusion Criteria: * Diagnosis of recurrent, unresectable, or metastatic DDLPS * The definition of recurrent disease is a patient with a primary tumor that has been successfully resected, but has recurred after primary surgery * Any number of prior systemic therapies will be allowed * Age ≥ 18 years at the time of informed consent * Willing and able to provide written informed consent/assent for the trial * Willing to comply with treatment protocol * Adequate performance status: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1/Karnofsky Performance Status (KPS) 70-100% * Presence of measurable disease per RECIST v1.1 o Target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression * QTc ≤ 480 msec using Fredericia's QT correction formula * Adequate organ function determined within 2 weeks of treatment initiation, defined as follows: * Hemoglobin ≥ 9.0 g/dL * Absolute neutrophil count ≥ 1,500/mm3 (1.0 x 109/L) * Platelet count ≥ 75,000/mm3 (50 x 109/L) * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) OR direct bilirubin ≤ ULN for a patient with total bilirubin level \> 1.5 x ULN * Aspartate aminotransferase (AST) ≤ 2.5 x ULN OR ≤ 5 x ULN for patients with liver metastases * Alanine aminotransferase (ALT) ≤ 2.5 x ULN OR ≤ 5 x ULN for patients with liver metastases * Alkaline phosphatase \< 5 x ULN * Serum creatinine ≤ 1.5 x ULN or a …